Prospective Collection of Surplus Surgical Tumor Tissues and Pre-surgical Blood Samples
18 Years
90 Years
Both
Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Hematologic Cancer
Trial Information
Prospective Collection of Surplus Surgical Tumor Tissues and Pre-surgical Blood Samples
This study will enroll subjects diagnosed with various cancers and who are scheduled to
undergo surgical treatment. Prior to scheduled surgery, subjects will be asked to donate a
10-20 ml blood sample. After surgery, surplus tissues (including tumor and adjacent normal
tissues) not required for diagnosis will be collected. Subject clinical information will be
collected, including basic demographic information, medical history, family history, current
cancer history and treatment. After surgery, a final pathology report will be obtained for
each subject's surgical specimen. In some instances and based on the cancer indications
required, longitudinal data may also be collected at a frequency of every 6 months to once
per year. Longitudinal data will include information on study subject survival and disease
recurrence.
Inclusion Criteria:
- Any adult age
- Any sex
- Able to provide consent for surplus tissue and/or blood donation
- Diagnosed with one of the cancer indications listed below:
- Scheduled to undergo surgical resection of tumor (exception for hematological
cancers)
- Have not yet received treatment for cancer
Exclusion Criteria:
- Not diagnosed with required cancer indication
- Not scheduled to undergo surgical resection of the tumor
- Have already received cancer treatment (such as chemotherapy, radiation, surgery) for
the current cancer or a previously diagnosed cancer
- Not able to donate an adequate volume of blood to meet minimum requirements
CANCER INDICATIONS:
1. Bladder Cancer - Urothelial carcinoma - nonpapillary
2. Bladder Cancer - Urothelial carcinoma - papillary
3. Brain Cancer - Astrocytoma
4. Brain Cancer - Glioblastoma
5. Brain Cancer - Medulloblastoma
6. Breast Cancer - Ductal Carcinoma
7. Breast Cancer - Lobular Carcinoma
8. Cervical Cancer - Squamous Cell Carcinoma
9. Colorectal Cancer - Adenocarcinoma
10. Esophageal Cancer - Adenocarcinoma
11. Gastric Cancer
12. Head and Neck Cancer - Squamous Cell Carcinoma
13. Hematologic Cancer - Acute Lymphocytic Leukemia (ALL)
14. Hematologic Cancer - Acute Myeloid Leukemia (AML)
15. Hematologic Cancer - Chronic Lymphocytic Leukemia (CLL)
16. Hematologic Cancer - Diffuse Large B‐cell Lymphoma
17. Hematologic Cancer - Multiple Myeloma (MM)
18. Hematologic Cancer - Non‐Hodgkins Lymphoma (NHL)
19. Kidney Cancer - Papillary Carcinoma
20. Kidney Cancer - Renal cell Carcinoma
21. Liver Cancer - Hepatocellular Carcinoma
22. Lung Cancer - Adenocarcinoma
23. Lung Cancer - Squamous Cell Cancer
24. Melanoma
25. Pancreatic Cancer - Ductal Adenocarcinoma
26. Prostate Cancer - Adenocarcinoma
27. Sarcomas
28. Thyroid Cancer - Follicular Carcinoma
29. Thyroid Cancer - Papillary Carcinoma
30. Uterine Cancer - Endometrial Carcinoma
Type of Study:
Observational
Study Design:
Time Perspective: Prospective
Outcome Measure:
Tumor genetic sequence variation
Outcome Description:
The specimens collected for this project will support genomic studies on the molecular basis of cancer. This study aims to collect specimens for a project that will systematically explore a spectrum of genomic changes involved in human cancer. Specifically the project will analyze DNA copy number changes, including large (on the order of chromosomal segments) and small (1,000 to 100,000 KB) scale rearrangements, transcription profiles, epigenetic modifications, sequence variation, and sequence in both tumor tissue and case-matched germline DNA. The suite of analysis platforms for collaborating laboratories will be applied to a common set of molecular analytes obtained from clinically annotated high-quality tumor specimens and case matched normal control specimens obtained form this specimen collection study. Initial measures critical to ensure specimen quality and qualification for subsequent analysis include confirmed histopathology and RNA integrity.
Outcome Time Frame:
up to 18 months
Safety Issue:
No
Principal Investigator
Neil R Mucci
Investigator Role:
Study Director
Investigator Affiliation:
Global BioClinical
Authority:
United States: Institutional Review Board
Study ID:
GBCPRT0008
NCT ID:
NCT01792882
Start Date:
February 2013
Completion Date:
December 2014
Related Keywords:
- Breast Cancer
- Colorectal Cancer
- Lung Cancer
- Prostate Cancer
- Hematologic Cancer
- Breast Neoplasms
- Colorectal Neoplasms
- Lung Neoplasms
- Prostatic Neoplasms
- Hematologic Neoplasms
Name | Location |
|---|---|
| GBC | Seattle, Washington 98104 |
